Vanda Pharmaceuticals Inc. 8-K

What Happened

• Vanda Pharmaceuticals Inc. filed an 8-K on June 5, 2026 reporting the results of its annual meeting held June 4, 2026. Of 60,135,062 shares entitled to vote, 48,509,906 shares (≈80.7%) were represented, constituting a quorum.
• Stockholders elected three Class II directors for three-year terms (until the 2029 annual meeting): Richard W. Dugan, Charles C. Duncan, Ph.D., and Anne Sempowski Ward. The meeting also ratified PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm, approved an advisory (non-binding) vote on named executive officer compensation, and approved an amendment to the company’s Amended and Restated 2016 Equity Incentive Plan to increase authorized shares.

Key Details

• Voting turnout: 48,509,906 shares voted in person or by proxy (≈80.7% of shares entitled to vote).
• Director election vote counts:
  • Richard W. Dugan — For: 33,029,049; Against: 5,417,322; Abstain: 46,718; Broker non-votes: 10,016,817.
  • Charles C. Duncan, Ph.D. — For: 35,780,031; Against: 2,664,889; Abstain: 48,169; Broker non-votes: 10,016,817.
  • Anne Sempowski Ward — For: 33,897,782; Against: 4,543,488; Abstain: 51,819; Broker non-votes: 10,016,817.
• Auditor ratification (PwC) — For: 48,103,698; Against: 340,513; Abstain: 65,695.
• Advisory vote on executive compensation — For: 35,242,659; Against: 3,167,243; Abstain: 83,187; Broker non-votes: 10,016,817.
• Amendment to 2016 Equity Incentive Plan approved — For: 31,729,991; Against: 6,685,078; Abstain: 78,020; Broker non-votes: 10,016,817.

Why It Matters

• Board continuity and governance: Election of the three directors confirms the Board’s composition for the next three years and supports continuity of leadership and oversight.
• Accounting and financial reporting: Ratification of PwC maintains continuity in external audit oversight for fiscal 2026.
• Shareholder sentiment: The advisory approval of executive compensation signals shareholder support (non-binding) for pay practices disclosed in the proxy.
• Equity-plan approval: Shareholder approval to increase authorized shares under the 2016 Plan enables the company to grant additional equity awards in the future, which can affect dilution and executive/employee incentives; the filing reports the vote but does not state the specific share increase amount.